Production of H5N1 (NIBRG-14) inactivated whole virus and split virion influenza vaccines and analysis of immunogenicity in mice using different adjuvant formulations

Vaccine

Volumn 28, Issue 13, 2010, Pages 2505-2509

  Miyaki, Cosue ^a   Quintilio, Wagner ^a   Miyaji, Eliane N ^b   Botosso, Viviane F ^a   Kubrusly, Flavia S ^b   Santos, Fernanda L ^a   Iourtov, Dmitri ^a   Higashi, Hisako G ^a   Raw, Isaias ^b  

^a Instituto/Fundacao Butantan   (Brazil)

^b INSTITUTO BUTANTAN   (Brazil)

Author keywords

Adjuvant; H5N1 influenza vaccine

Indexed keywords

ALUMINUM HYDROXIDE; HEMAGGLUTINATION INHIBITING ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; OVALBUMIN; PHOSPHORYL LIPID A; SPLIT VIRION VACCINE; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY TITER; AQUEOUS SOLUTION; ARTICLE; BORDETELLA PERTUSSIS; CONTROLLED STUDY; DRUG FORMULATION; EGG; EMULSION; FEMALE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; VIRION;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM HYDROXIDE; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BORDETELLA PERTUSSIS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; LIPID A; MICE; MICE, INBRED BALB C; OVALBUMIN; VACCINES, INACTIVATED; VACCINES, SUBUNIT;

EID: 77649179583     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.01.044     Document Type: Article

References (21)

1. WHO. Cumulative number of confirmed human cases of avian influenza a/(H5N1) reported to WHO (2009). http://www.who.int/csr/disease/avian_influenza/country/cases_table_2009_09_24/en/index.html [cited; available from: http://www.who.int/csr/disease/avian_influenza/country/cases_table_2009_09_24/en/index.html]
2. Oshitani H., Kamigaki T., and Suzuki A. Major issues and challenges of influenza pandemic preparedness in developing countries. Emerg Infect Dis 14 June (6) (2008) 875-880
3. Leroux-Roels I., and Leroux-Roels G. Current status and progress of prepandemic and pandemic influenza vaccine development. Expert Rev Vaccines 8 April (4) (2009) 401-423
4. Zorzeto T.Q., Higashi H.G., da Silva M.T., Carniel Ede F., Dias W.O., Ramalho V.D., et al. Immunogenicity of a whole-cell pertussis vaccine with low lipopolysaccharide content in infants. Clin Vaccine Immunol 16 April (4) (2009) 544-550
5. Quintilio W., Kubrusly F.S., Iourtov D., Miyaki C., Sakauchi M.A., Lucio F., et al. Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice. Vaccine 27 June (31) (2009) 4219-4224
6. Wood J.M., and Robertson J.S. From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat Rev Microbiol 2 October (10) (2004) 842-847
7. WHO. WHO manual on animal influenza-diagnosis and surveillance WHO/CDS/CSR/NCS/2002.5 (2002). http://www.who.int/vaccine_research/diseases/influenza/WHO_manual_on_animal-diagnosis_and_surveillance_2002_5.pdf [cited; available from: http://www.who.int/vaccine_research/diseases/influenza/WHO_manual_on_animal-diagnosis_and_surveillance_2002_5.pdf]
8. WHO. Recommendations for the production and control of influenza vaccine (inactivated). WHO Technical Report Series (2005). http://www.who.int/biologicals/publications/trs/areas/vaccines/influenza/en/index.html [cited Annex 3 927; available from: http://www.who.int/biologicals/publications/trs/areas/vaccines/influenza/en/index.html]
9. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354 March (13) (2006) 1343-1351
10. De Gregorio E., Tritto E., and Rappuoli R. Alum adjuvanticity: unraveling a century old mystery. Eur J Immunol 38 August (8) (2008) 2068-2071
11. Lin J., Zhang J., Dong X., Fang H., Chen J., Su N., et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368 September (9540) (2006) 991-997
12. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 May (9523) (2006) 1657-1664
13. Ehrlich H.J., Muller M., Oh H.M., Tambyah P.A., Joukhadar C., Montomoli E., et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 358 June (24) (2008) 2573-2584
14. Keitel W.A., Campbell J.D., Treanor J.J., Walter E.B., Patel S.M., He F., et al. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis 198 November (9) (2008) 1309-1316
15. Song M.S., Oh T.K., Pascua P.N., Moon H.J., Lee J.H., Baek Y.H., et al. Investigation of the biological indicator for vaccine efficacy against highly pathogenic avian influenza (HPAI) H5N1 virus challenge in mice and ferrets. Vaccine 27 May (24) (2009) 3145-3152
16. Bernstein D.I., Edwards K.M., Dekker C.L., Belshe R., Talbot H.K., Graham I.L., et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 197 March (5) (2008) 667-675
17. Reed S.G., Bertholet S., Coler R.N., and Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 30 January (1) (2009) 23-32
18. Mata-Haro V., Cekic C., Martin M., Chilton P.M., Casella C.R., and Mitchell T.C. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316 June (5831) (2007) 1628-1632
19. Hagenaars N., Mastrobattista E., Glansbeek H., Heldens J., van den Bosch H., Schijns V., et al. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model. Vaccine 26 December (51) (2008) 6555-6563
20. Geeraedts F., Goutagny N., Hornung V., Severa M., de Haan A., Pool J., et al. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog 4 8 (2008) e1000138
21. Banzhoff A., Pellegrini M., Del Giudice G., Fragapane E., Groth N., and Podda A. MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Respir Viruses 2 November (6) (2008 Nov) 243-249